Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

A new cell therapy registry coordinated by the European Group for Blood and Marrow Transplantation (EBMT)

Bone Marrow Transplantation volume 41, page 319 (2008)Cite this article

Novel cell therapies include cell preparations defined by various criteria and may be applicable to patients suffering from autoimmune, neurologic and hematologic disorders as well as heart diseases and so on. The therapeutic potential of, for example, cytotoxic T cells, tumor vaccines and mesenchymal stem cells (MSCs) is undergoing extensive clinical testing in areas such as cancer, tissue repair in connective tissue disorders and heart repair as well as immune modulation in the setting of stem cell transplantation. In other areas, including immunological disorders such as rheumatoid arthritis and vasculitides, MSC treatment is about to enter the clinical arena.

Although these therapies may be promising and prove to be of clinical use, clinical trials are often small with a limited follow-up. Detection of long-term beneficial effects, as well as late and rare side effects, would require a large number of patients followed over many years. Little is known of the in vivo risks of infused cell products manipulated or expanded ex vivo. A risk of ectopic tissue formation, malignant transformation of the cell product or secondary malignancies, as observed occasionally in certain experimental animal models, may or may not pose true clinical risks.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

    K Le Blanc

  2. Hematology Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

    K Le Blanc

  3. Department of Immunohematology and Bloodbank, Leiden University Medical Center, Leiden, The Netherlands. E-mail: katarina.Leblanc@ki.se,

    W Fibbe

Authors
  1. K Le Blanc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W Fibbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Developmental Committee of the EBMT

Rights and permissions

Reprints and permissions

About this article

Cite this article

Le Blanc, K., Fibbe, W. & on behalf of the Developmental Committee of the EBMT. A new cell therapy registry coordinated by the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 41, 319 (2008). https://doi.org/10.1038/sj.bmt.1705920

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705920

This article is cited by

Search

Advanced search

Quick links